Abstract

Chronic kidney disease (CKD) is a common health issue affecting 8% to 16% of the global population. This condition often co-occurs with other health complications, such as thyroid dysfunction, dyslipidemia, and cardiovascular diseases. Aim: The objective of this study was to evaluate the potential association between cystatin C, vitamin D, and thyroid hormone levels in patients with CKD. Materials and Methods: The study recruited a total of 250 patients diagnosed with CKD. Demographic information, biochemical data, and hormone levels of all the patients were collected and analyzed. The analytes measured included serum creatinine, cystatin C, vitamin D, free thyroxine (fT4), and thyroid stimulating hormone (TSH). Auto-analyzers were used for evaluating these variables, and all the results were recorded and analyzed using SPSS software. Results: The mean serum creatinine level was 2.39 mg/dl, while the mean vitamin D and cystatin C levels were 37.5 ng/mL and 3.9 mg/L, respectively. The mean TSH level was 3.29 mU/L, and the mean free thyroxine level was 1.45ng/mL. The results showed that 16%, 24%, 24%, 20%, and 16% of the patients were classified as CKD stages I, II, III, IV, and V, respectively. The correlation between CKD grading and cystatin C levels was found to be significant. Conclusion: The study suggests that most patients with chronic kidney disease have altered serum cystatin C levels that increase with disease progression. Cystatin C appears to be a sensitive biomarker for detecting early declines in renal function

Description